Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAR-221 in untreated advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma
jRCT2051220179Phase 3Active, not recruiting
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) comparing Domvanalimab + zimberelimab + chemotherapy with Nivolumab + chemotherapy (2 arms). Primary endpoint: Overall survival. Started Jun 2023; status: active, not recruiting.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on jRCT2051220179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220179.